Recurrent CMV disease has been reported to occur in 6% to 59% of solid-organ transplant
recipients. The consequences of recurrent CMV disease after the treatment of the first CMV …

CMV infection is a major cause of morbidity in patients receiving solid organ transplants.
CMV is widely distributed in the general population with seroprevalence ranging from 30 to …

Recent research has led to the identification of risk factors for cytomegalovirus (CMV)
infection and disease in the solid organ transplant patient, leading to increasingly effective …

C ytomegalovirus (CMV) is the major viral pathogen in renal and other solid organ transplant
recipients and may cause serious morbidity which includes fever with leukopenia …

• Tissue-invasive cytomegalovirus (TI-CMV) disease occurs commonly after solid organ
transplantation and has been associated with increased allograft loss and patient mortality …

Background. Recurrent infection frequently follows the response to the initial treatment of
cytomegalovirus (CMV) infection in solid-organ transplant (SOT) recipients. The objective of …

After allotransplantation, cytomegalovirus (CMV) may be transmitted from the donor organ,
giving rise to primary infection in a CMV negative recipient or reinfection in one who is CMV …

Background. Previous studies suggest a link between cytomegalovirus (CMV) infection and
chronic rejection. Since these studies, more sophisticated diagnostic methods with high …

Background Although initial therapy for cytomegalovirus (CMV) is usually successful, a
significant subset of patients may have recurrent viremia. However, the epidemiology and …

BACKGROUND: Late-onset CMV disease is being increasingly recognized as a significant
post-transplantation complication. OBJECTIVES: To discern the impact of antiviral …